News

The Clinical Trial Application (CTA) has been submitted to the MPA

It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC)

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in Canada. Previously patent has been granted in the USA, the EU, Japan, Australia and China. Canada was the last major country remaining for PN6047.

PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer. Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies.

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.